O. M. Ghoneim, J. A. Legere, A. Golbraikh, A. Tropsha and R. G. Booth, “Novel Ligands for the Human Histamine H1 Receptor: Synthesis, Pharmacology, and Comparative Molecular Field Analysis Studies of 2-Dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes,” Bioorganic & Medicinal Chemistry, Vol. 14, No. 19, 2006, pp. 6640-6658. doi:10.1016/j.bmc.2006.05.077

has been cited by the following article:

• TITLE: 5-HT2A Receptor Activation Normalizes Exaggerated Fear Behavior in p-Chlorophenylalanine (PCPA)-Treated Rats

  AUTHORS: Cathryn R. Hughes, Lee Tran, N. Bradley Keele

  KEYWORDS: Fear Conditioning; Startle Reflex; 5-HT2; DOI; Ketanserin; SB 206553

  JOURNAL NAME: Journal of Behavioral and Brain Science, Vol.2 No.4, November 30, 2012

  ABSTRACT: Deficits in serotonin (5-hydroxytryptamine, 5-HT) neurotransmission are implicated in abnormal emotional behaviors such as aggression, anxiety, and depression. However, the specific 5-HT receptor mechanisms involved are not well understood. The role of 5-HT2 receptors in fear potentiated startle, (FPS) was examined in rats chronically treated with pchlorophenylalanine (PCPA) to reduce brain 5-HT. PCPA-treated rats show an enhanced magnitude of FPS. Systemic administration of the 5-HT2 receptor agonist (±)-2,5-Dimethoxy-4-iodoamphetamine hydrochloride (DOI) reduced FPS in both PCPA-treated and saline (SAL)-treated control animals, normalizing the exaggerated fear response in PCPA-treated rats. In both SAL- and PCPA-treated animals, the DOI-induced reduction of learned fear was reversed by the 5-HT2 antagonist ketanserin, but not by the 5-HT2B/2C antagonist SB 206553. Together, these findings suggest 5-HT2A receptors are critical regulators of learned fear, and that 5-HT2A receptors may be an important pharmacological target to normalize exaggerated learned fear resulting from chronic 5-HT-ergic disruption.